After four years of follow-up, Keytruda (pembrolizumab) plus Lenvima (lenvatinib) maintained a clinically meaningful overall survival benefit versus sunitinib in the phase III CLEAR (Study 307)/KEYNOTE-581 trial of first-line treatment in patients with advanced renal cell carcinoma.
Addition of the immunotherapy drug pembrolizumab (Keytruda) to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the results of the SU2C-SARC032 clinical trial led by researchers from the University of Pittsburgh, UPMC, Duke University, and Princess Margaret Cancer Centre.
